Literature DB >> 24107928

Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.

L N Eadie1, T P Hughes2, D L White2.   

Abstract

The efflux transporters adenosine triphosphate (ATP)-binding cassette (ABC)B1 and ABCG2 have been demonstrated to interact with the tyrosine kinase inhibitors (TKIs) imatinib, nilotinib, and dasatinib. However, although some studies conclude that TKIs are substrates of one or both transporters, other studies demonstrate only an inhibitory function. This variation is probably due to differences in the concentration of TKIs assayed and the experimental systems used. This article examines the evidence for clinically relevant interactions between three currently approved TKIs and ABCB1/ABCG2.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24107928     DOI: 10.1038/clpt.2013.208

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  27 in total

1.  Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo.

Authors:  Caroline Ebert; Florian Perner; Denise Wolleschak; Tina M Schnöder; Thomas Fischer; Florian H Heidel
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

2.  The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.

Authors:  Susan L Holbeck; Richard Camalier; James A Crowell; Jeevan Prasaad Govindharajulu; Melinda Hollingshead; Lawrence W Anderson; Eric Polley; Larry Rubinstein; Apurva Srivastava; Deborah Wilsker; Jerry M Collins; James H Doroshow
Journal:  Cancer Res       Date:  2017-04-26       Impact factor: 12.701

Review 3.  Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors.

Authors:  Marjan Yaghmaie; Cecilia Cs Yeung
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

4.  The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.

Authors:  L N Eadie; P Dang; V A Saunders; D T Yeung; M P Osborn; A P Grigg; T P Hughes; D L White
Journal:  Leukemia       Date:  2016-06-24       Impact factor: 11.528

Review 5.  The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?

Authors:  Naranie Shanmuganathan; Susan Branford
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 6.  Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.

Authors:  Marie Lund; Tonny Studsgaard Petersen; Kim Peder Dalhoff
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

7.  Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study.

Authors:  Mahmoud A A Ibrahim; Esraa A A Badr; Alaa H M Abdelrahman; Nahlah Makki Almansour; Ahmed M Shawky; Gamal A H Mekhemer; Faris Alrumaihi; Mahmoud F Moustafa; Mohamed A M Atia
Journal:  Cell Biochem Biophys       Date:  2021-05-05       Impact factor: 2.194

8.  ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.

Authors:  Q Zheng; H Wu; Q Yu; D H Dennis Kim; J H Lipton; S Angelini; S Soverini; D Vivona; N Takahashi; J Cao
Journal:  Pharmacogenomics J       Date:  2014-09-23       Impact factor: 3.550

Review 9.  Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Authors:  Ami B Patel; Thomas O'Hare; Michael W Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2017-08       Impact factor: 3.722

10.  Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.

Authors:  Poe-Hirr Hsyu; Daniela Soriano Pignataro; Kyle Matschke
Journal:  Eur J Clin Pharmacol       Date:  2016-10-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.